Our technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, with the potential to create high-quality, long-lasting antibodies with the potential to resist viral escape. Our products can be tuned to improve potency, breadth of neutralization, and half-life, and can be developed for use in both prevention and treatment of disease.
With our powerful proprietary platform approach, we are generating a pipeline of next-generation engineered antibodies for the prevention and treatment of viral infectious diseases, starting with SARS-CoV-2. Our discovery efforts in this disease area are focused on broadly neutralizing antibodies that target conserved epitopes across multiple members of the coronavirus family.
CORONAVIRUSES: A CONTINUED GLOBAL BURDEN
Coronaviruses comprise a large family of viruses that are grouped into four genera: alphacoronavirus, betacoronavirus, gammacoronavirus and deltacoronavirus. Over the past 20 years, three pathogenic novel betacoronaviruses have spilled over into the human population from animal reservoirs to cause outbreaks of deadly pneumonia, including SARS-CoV-2, SARS and MERS.
COVID-19, the disease caused by SARS-CoV-2 and its variants, has given rise to a global pandemic that swept rapidly throughout the world in 2020 and 2021 and continues to disrupt global supply chains and cause significant global burden.
SARS-CoV-2 and the human antibody response are in a perpetual cycle of co-evolution. Weak antibody responses cannot suppress the virus completely, allowing repeat infection, mutation‚ and the rise of new variants that can escape established immunity.
OUR SOLUTION
We believe that engineered antibodies that robustly and durably protect humans from SARS-CoV-2 have the following characteristics:
- Provide superior protection compared to human antibodies induced by vaccination and infection
- Highly potent and broadly neutralizing activity to address SARS-CoV-2, including variants of concern
- Easily accessible and patient friendly with a single outpatient administration
- Can be deployed in advance to prevent disease, or once sick to treat disease
Invivyd’s discovery technology and platform are designed to overcome the challenges of viral evolution through ongoing innovation. With our platform approach, we are determined to change the paradigm for managing viral infections and powering the return to normal by delivering rapid and lasting antibody immunity to protect the general public and ensure vulnerable populations are never left behind.
Pipeline
Leveraging our integrated discovery platform, we have built a robust pipeline of antibody candidates for the prevention and treatment of COVID-19, including, VYD222 a novel antibody. VYD222 is a monoclonal antibody candidate that has demonstrated in vitro neutralizing activity against variants of concern, including XBB.1.5. VYD222 has been engineered, optimizing for potency and breadth of coverage, as well as to provide a higher probability of retaining its utility for a longer duration in an evolving viral landscape. The antibody targets a site under minimal immune pressure, not readily targeted by the common human immune repertoire. We believe this will reduce the likelihood of immune escape. Not only does this provide an attractive option for treatment of disease, but by engineering our antibodies for extended half-life, a single administration has potential to offer durable protection.
VYD222 was engineered from adintrevimab (ADG20), which provided neutralizing protection against SARS-CoV-2 for all variants of concern until the emergence of the Omicron BA.2 strain and its sublineages.
But we won’t stop there. We vigilantly monitor the evolving viral variants and continuously identify multiple new antibody candidates that provide broad in vitro neutralizing activity against past, current, and potential future variants of concern. Our goal is to always be innovating to match whatever challenges the virus presents with novel products for prevention and treatment of disease.
Publications & Presentations
– – – – – – –
Assessment of Effect of Adintrevimab on COVID-19 Vaccine Response
ISIRV-AVG 2023
– – – – – – –
NVD200 potently neutralizes Omicron and its sublineages
ECCMID 2023
– – – – – – –
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers
Science Translational Medicine
– – – – – – –
ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19, demonstrated broad in vitro neutralisation against SARS-CoV-2 variants
ECCMID 2022
– – – – – – –
Population pharmacokinetics of ADG20, an extended–half-life monoclonal antibody being developed for the treatment and prevention of COVID-19
ECCMID 2022
– – – – – – –
Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Adintrevimab (ADG20) in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP)
ASM Microbe 2022
– – – – – – –
Broad and Potent In Vitro Neutralization of SARS-CoV-2 Variants by ADG20, a Half-Life–Extended Monoclonal Antibody in Development for the Prevention and Treatment of COVID-19
ISIRV-WHO 2021
– – – – – – –
Evaluating the Safety, Tolerability, and Pharmacokinetics of ADG20, a Half-Life–Extended Monoclonal Antibody (mAb) in Development for the Prevention and Treatment of COVID-19: a Preliminary Analysis of a Randomized Phase 1 Study
ISIRV-WHO 2021
– – – – – – –
A Whole-Body Quantitative System Pharmacology Physiologically Based Pharmacokinetic Model That a Priori Predicts Pharmacokinetics of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of COVID-19
IDWeek 2021
– – – – – – –
IDWeek 2021
– – – – – – –
IDWeek 2021
– – – – – – –
IDWeek 2021
– – – – – – –
ECCMID 2021
– – – – – – –
ECCMID 2021
– – – – – – –
Nature Medicine
– – – – – – –
Science Immunology
– – – – – – –
Structural Basis of Zika Virus Specific Neutralization in Subsequent Flavivirus Infections
MDPI
– – – – – – –
Rational Vaccine Design in the Time of COVID-19
Cell Host Microbe
– – – – – – –
Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
Science
– – – – – – –
An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19
BioRxiv
– – – – – – –
Wec AZ et al. Broad neutralization of SARS-related antibodies by human monoclonal antibodies. Science. 2020 Jun 15.
Science
– – – – – – –
Wec AZ et al. Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine. Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6675-6685.
Proceedings of the National Academy of Sciences (PNAS)
– – – – – – –
Shehata L et al. Systematic comparison of respiratory syncytial virus-induced memory B cell responses in two anatomical compartments. Nat Commun. 2019 Mar 8; 10(1):1126.
Nature Communications
– – – – – – –
West BR et al. Structural basis of broad ebolavirus neutralization by a human survivor antibody. Nat Struct Mol Biol. 2019 Mar; 26(3):204-212.
Nature Structural and Molecular Biology
– – – – – – –
Bornholdt ZA et al. A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. Cell Host Microbe. 2019 Jan 9; 25(1):49-58.e5.
Cell Host and Microbe
– – – – – – –
Wec AZ et al. Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection. Cell Host Microbe. 2019 Jan 9; 25(1):39-48.e5.
Cell Host and Microbe
– – – – – – –
Saphire EO et al. Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection (2018). Cell. Aug 09; 174(4):938-952.
Cell
– – – – – – –
Goodwin E et al. Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation (2018). Immunity. Feb 20; 48(2):339-349
Immunity
– – – – – – –
Walker LM et al. Passive immunotherapy of viral infections: ‘super-antibodies’ enter the fray (2018). Nat Rev Immunol. May; 18(5):297-308.
Nature Reviews Immunology
– – – – – – –
Rogers TF et al. Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors (2017). Sci Immunol. Aug 18; 2(14).
Science Immunology
– – – – – – –
Wec AZ et al. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses (2017). Cell. May 18; 169(5):878-890.
Cell
– – – – – – –
Gilman MS et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors (2016). Sci Immunol. Dec 16; 1(6).
Science Immunology
– – – – – – –
Badarau A et al. Context matters: The importance of dimerization-induced conformation of the LukGH leukocidin of Staphylococcus aureus for the generation of neutralizing antibodies (2016). MAbs. Jul 28:0.
mAbs
– – – – – – –
Bornholdt ZA et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak (2016). Science. Mar 4;351(6277):1078-83.
– – – – – – –
Walker LM et al. Broad neutralization coverage of HIV by multiple highly potent antibodies (2011). Nature. Aug 17;477(7365):466-470.
Nature
– – – – – – –
Walker LM et al. Rational antibody-based HIV-1 vaccine design: current approaches and future directions (2010). Curr Opin Immunol. Jun; 22(3):358-66.
Science Direct
– – – – – – –
Walker LM et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target (2009). Science. 326(5950):285-9.
Science